Similar articles for PMID: 31250942

Year	Number of Results
1996	1
1999	1
2003	2
2004	1
2006	2
2008	3
2009	2
2010	4
2011	2
2012	10
2013	7
2014	7
2015	5
2016	9
2017	23
2018	27
2019	28
2020	27
2021	35
2022	36
2023	16
2024	0

1

Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.

Inao T, Kotani H, Iida Y, Kartika ID, Okimoto T, Tanino R, Shiba E, Harada M. Inao T, et al. Cancer Sci. 2019 Sep;110(9):2690-2699. doi: 10.1111/cas.14116. Epub 2019 Jul 23. Cancer Sci. 2019. PMID: 31250942 Free PMC article.

2

Protective role of cytoplasmic p21Cip1/Waf1 in apoptosis of CDK4/6 inhibitor-induced senescence in breast cancer cells.

Kartika ID, Kotani H, Iida Y, Koyanagi A, Tanino R, Harada M. Kartika ID, et al. Cancer Med. 2021 Dec;10(24):8988-8999. doi: 10.1002/cam4.4410. Epub 2021 Nov 11. Cancer Med. 2021. PMID: 34761877 Free PMC article.

3

CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.

Zhang QF, Li J, Jiang K, Wang R, Ge JL, Yang H, Liu SJ, Jia LT, Wang L, Chen BL. Zhang QF, et al. Theranostics. 2020 Aug 25;10(23):10619-10633. doi: 10.7150/thno.44871. eCollection 2020. Theranostics. 2020. PMID: 32929370 Free PMC article.

4

NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.

Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW. Ruscetti M, et al. Science. 2018 Dec 21;362(6421):1416-1422. doi: 10.1126/science.aas9090. Science. 2018. PMID: 30573629 Free PMC article.

5

Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.

Cersosimo RJ. Cersosimo RJ. Am J Health Syst Pharm. 2019 Aug 1;76(16):1183-1202. doi: 10.1093/ajhp/zxz121. Am J Health Syst Pharm. 2019. PMID: 31369120 Review.

6

Ginsenoside Rh2 Ameliorates Doxorubicin-Induced Senescence Bystander Effect in Breast Carcinoma Cell MDA-MB-231 and Normal Epithelial Cell MCF-10A.

Hou JG, Jeon BM, Yun YJ, Cui CH, Kim SC. Hou JG, et al. Int J Mol Sci. 2019 Mar 12;20(5):1244. doi: 10.3390/ijms20051244. Int J Mol Sci. 2019. PMID: 30871042 Free PMC article.

7

Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.

Tamura K. Tamura K. Jpn J Clin Oncol. 2019 Dec 18;49(11):993-998. doi: 10.1093/jjco/hyz151. Jpn J Clin Oncol. 2019. PMID: 31665472 Review.

8

Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.

Palumbo A, Lau G, Saraceni M. Palumbo A, et al. Ann Pharmacother. 2019 Feb;53(2):178-185. doi: 10.1177/1060028018795146. Epub 2018 Aug 13. Ann Pharmacother. 2019. PMID: 30099886 Review.

9

Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging.

Muñoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, Freund AM, Rodier F, Wu JD, Desprez PY, Raulet DH, Nelson PS, van 't Veer LJ, Campisi J, Coppé JP. Muñoz DP, et al. JCI Insight. 2019 Jun 11;5(14):e124716. doi: 10.1172/jci.insight.124716. JCI Insight. 2019. PMID: 31184599 Free PMC article.

10

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.

Corona SP, Generali D. Corona SP, et al. Drug Des Devel Ther. 2018 Feb 16;12:321-330. doi: 10.2147/DDDT.S137783. eCollection 2018. Drug Des Devel Ther. 2018. PMID: 29497278 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

215 results

Results by year